Background: Liver cancer is the fifth most commonly diagnosed cancer and the second
leading cause of cancer-related deaths worldwide. Among the liver cancers, hepatocellular …

Highlights: Multi tyrosine kinase inhibitors licensed for HCC treatment. Multi kinase inhibitors
not licensed for HCC treatment. Inhibitors of Growth Factor Receptors. Small molecules …

Background N6-methyladenosine (m6A) methylation and ferroptosis assist long noncoding
RNAs (lncRNAs) in promoting immune escape in hepatocellular carcinoma (HCC) …

Hepatocellular carcinoma (HCC) has long been a major global clinical problem as one of
the most common malignant tumours with a high rate of recurrence and mortality. Although …

The effect of targeted therapy for metastatic hepatocellular carcinoma (HCC) is still
unsatisfactory. Exploring the underlying mechanism of HCC metastasis is favorable to …

Introduction: Hepatocellular carcinoma (HCC) is the fifth most diagnosed cancer in the world
and the third leading cause of death. Unfortunately, when diagnosed two thirds of patients …

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors worldwide,
with nearly one million new cases and deaths every year. Owing to the complex …

Hepatocellular carcinoma (HCC) is an aggressive tumor that often arises in the setting of
liver cirrhosis. Although early-stage disease is often amenable for surgical resection …

Breast cancer is a group of diseases in which cells divide out of controlled, typically resulting
in a mass. Erlotinib is targeted cancer drug which functions as an inhibitor of the epidermal …

Erlotinib, an EGFR tyrosine kinase inhibitor has been introduced into cancer chemotherapy.
However, the therapeutic effects of erlotinib in hepatocellular carcinoma (HCC) remain …